PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 mo vs >12 mo From Kidney Biopsy
MA-SP-25-0214 | November 2025
Congress Materials
Explore our congress materials
Encore posters are re-presentations of previously published data.
Filter by:
Year
Year
×Event
Event
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Filter by:
Year
Year
×Event
Event
×Therapeutic area
Therapeutic area
×Disease area
Disease area
×Product
Product
×Study/Registry
Study/Registry
×Resource type
Resource type
×Results151
Sort by
How Does Nephrotic-Range Proteinuria Differ From Nephrotic Syndrome in Focal Segmental Glomerulosclerosis (FSGS)?
GlomCon Hawaii – 2026
In DUPLEX, Patients With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan vs Irbesartan Regardless of Baseline Proteinuria
GlomCon Hawaii – 2026
The Effect of Sparsentan on Proteinuria and Urinary Inflammatory and Profibrotic Biomarkers by Baseline Proteinuria Strata in SPARTAN Study Participants With IgA Nephropathy
GlomCon Hawaii – 2026
In DUPLEX, Patients With Focal Segmental Glomerulosclerosis (FSGS) Reached Low Proteinuria More Often With Sparsentan vs Irbesartan Regardless of Baseline Proteinuria
GlomCon Hawaii – 2026
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 Months vs >12 Months From Kidney Biopsy
GlomCon Hawaii – 2026
PROTECT Post Hoc Analysis: Efficacy of Sparsentan vs Irbesartan in Patients With IgA Nephropathy ≤12 Months vs >12 Months From Kidney Biopsy
GlomCon Hawaii – 2026
Join the
Conversation
Sign up to receive updates on the latest news, resources, and data on rare disease research.
Subscribe now
Connect with our MSL team today
Arrange a meeting with a member of our medical science liaison (MSL) team to discuss the latest insights, clinical trial data, and management trends.
Find your MSL